相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prediction of cytogenetic abnormalities with gene expression profiles
Yiming Zhou et al.
BLOOD (2012)
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
K. D. Boyd et al.
LEUKEMIA (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
Christina M. Annunziata et al.
BLOOD (2011)
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J. Morgan et al.
LANCET (2010)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27(Kip1)-dependent and -independent mechanisms
Fenghuang Zhan et al.
BLOOD (2007)
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
R. Fonseca et al.
LEUKEMIA (2006)
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Suzanne Trudel et al.
BLOOD (2006)
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
J Chen et al.
ONCOGENE (2005)
Molecular pathogenesis and a consequent classification of multiple myeloma
PL Bergsagel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
PL Bergsagel et al.
BLOOD (2005)
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
JJ Keats et al.
BLOOD (2003)
分享论文
